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TO THE EDITOR
Primary cutaneous diffuse large B-cell
lymphoma leg type (PCDLBCL-LT) is a
unique entity (ICD-O code 9680/3)
individualized from other primary
cutaneous B-cell lymphomas (PCBCL)
and from nodal B-cell lymphomas by
three main clinical features: preferential
leg localization, occurrence in the
elderly, and poor prognosis with a
45% 5-year survival rate (Vermeer
et al., 1996; Meijer et al, 2008).
In nodal DLBCL, gene expression
profiling has identified two main signa-
tures, indicative of either germinal
center (GC) or post-germinal center–-
activated B-cell (ABC) stages of B-cell
differentiation (Alizadeh et al., 2000).
The ABC or post-GC type of DLBCL
exhibits a poor overall survival together
with a constitutive activation of the
NF-kB pathway and a higher prolifera-
tion index (Lenz and Staudt, 2010).
Interestingly, the expression profile of
PCDLBCL-LT is similar to that of the ABC
type with constitutive NF-kB pathway
activation and strong expression of the
IRF4/MUM1B-cell transcription factor,
whereas primary cutaneous follicle cen-
ter lymphoma (PCFCL), even with large
cell morphology, belongs to the GC-like
category (Hoefnagel et al., 2005; Meijer
et al, 2008). An RNA interference screen-
ing for genes implicated in proliferation
or survival of nodal B-cell lymphoma led
to identify oncogenically active MYD88
mutations in 29% of nodal ABC-type
DLBCL (Ngo et al., 2011). This prompted
us to investigate the MYD88 gene status
in PCDLBCL-LT.
According to the Declaration of
Helsinki Principles, the study was
conducted after approval from the
regional bioethics committee with in-
formed written consent from the patient.
Skin samples from 38 patients were ana-
lyzed: 16 with PCDLBCL-LT, 14 with
PCFCL, 4 with primary cutaneous
marginal-zone lymphoma (PCMZL),
and 4 with secondary cutaneous DLBCL.
For PCDLBCL-LT and secondary cuta-
neous DLBCL, the tumor cell content
was estimated above 80% on routine
sections and after immunostaining.
PCFCL and PCMZL cases were similarly
selected from surgical skin biopsies
containing tumor cell content above
20%. DNA was extracted from frozen
material in 35 cases and from formalin-
fixed material in 3 cases with the
QIAGEN DNA easy kit (QIAGEN,
Courtaboeuf, France). Constitutional
DNA was extracted from blood samples
matched to patients. Sanger sequencing
of MYD88 was accomplished with the
following primers: 50-TCCCATGGAGC
TCTGACCAC-30 and 50-TAGSAGGAGA
TGCCCAGTAT-30 (PCR amplification
and sequencing exon 3); 50-ATGCTGAA
CTAAGTTGCCACA-30 and 50-GAGGC
CCCACCTACACATTC-30 (PCR amplifi-
cation and sequencing exon 4); 50-CTG
GGGTTGAAGACTGGGCT-30 and 50-A
TGGACAGGCAGACAGATAC-30 (PCR
amplification and sequencing exon 5.
The sequence of each amplified frag-
ment was determined on both strands
with the Big Dye Terminator v1.1 ready
reaction cycle sequencing kit (Applied
Biosystems, Villebon-sur-Yvette, France).
Among 16 cases of PCDLBCL-LT
tested, a thymine to cytosine base
transition at position 794 of the com-
plementary DNA coding sequence
(c. 794 T4C), causing a L265P—leucine
to proline—amino-acid mutation, was
detected in 11 cases (69%) (Table 1).
All cases harboring the L265P mutation
appeared heterozygous, as both normal
and mutated alleles were detected at
similar levels (Figure 1). None of our
samples harbored any of the other
mutations of MYD88 identified in nodal
B-cell lymphoma cases (V217F, W218R,
S219C, I220T, S222R, M232T, S243N,
T294P) (Ngo et al., 2011). In six
PCDLBCL-LT cases for which matched
germline DNA was available, the L265P
MYD88 gene mutation was shown to be
somatically acquired (Figure 1, Table 1).
Clinical features of PCDLBCL-LT with
L265P mutation (11/16, 69%) did not
differ from those without MYD88 muta-
tion (5/16, 31%). No correlation was
found with prognosis (overall survival,
progression free survival, time to relapse
or specific death) or response to therapy
(Table 1).
The MYD88 mutation was found to
be specific for PCDLBCL-LT among
other PCBCLs. None of the 14 PCFCL
cases (three of them with large cell
morphology) and none of the 4 PCMZL
Abbreviations: ABC, activated B cell; DLBCL, diffuse large B-cell lymphoma; GC, germinal center;
PCBCL, primary cutaneous B-cell lymphoma; PCFCL, primary cutaneous follicle center lymphoma;
PCDLBCL-LT, primary cutaneous diffuse large B-cell lymphoma, leg type; PCMZL, primary cutaneous
marginal zone lymphoma
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cases displayed any MYD88 mutation.
A more extensive study of the PCMZL
category would be relevant. A peculiar
case of PCFCL with small-cell morpho-
logy followed by secondary extra-
cutaneous nodal involvement with
large-cell transformation did not carry
MYD88 mutation at both sites. The
MYD88 L265P mutation was found in
one of the four secondary cutaneous
DLBCL cases and cannot be used in
differential diagnosis between primary
and secondary cutaneous DLBCL. More-
over, L265P mutation and other non-
synonymous mutations of the MYD88
gene have been identified by massive
parallel sequencing at lower frequencies
in chronic lymphocytic leukemia (10%)
and in gastric mucosa–associated
lymphoid tissue (MALT) lymphoma
(9%) (Ngo et al., 2011; Wang et al.,
2011).
Nodal ABC DLBCL may also harbor
several genetic alterations involving
PRDM1/BLIMP1 (Pasqualucci et al.,
2006; Mandelbaum et al., 2010),
CARD11 CD79A/B, and/or TNFAIP3
(also known as A20) genes (Lenz et al.,
2008a; Kato et al., 2009; Davis et al.,
2010). These alterations may overlap
with MYD88 mutations, and the
coding genome of DLBCL was shown
to contain 430 clonally represented
gene alterations per case (Ngo et al.,
2011; Pasqualucci et al., 2011). Somatic
hypermutation caused by sustained
activation-induced cytidine deaminase
(AID) activity has been found to con-
tribute to several genetic mutations in
cutaneous PCDLBCL-LT, as reported in
nodal DLBCL (Dijkman et al., 2006;
Pasqualucci et al., 2011). The T4C tran-
sition accounting for the L265P MYD88
mutation cannot result from deamina-
tion of 5-methylcytosine residues but
from other mechanisms driving the rapid
development of PCDLBCL-LT at such
site in elderly patients.
MYD88 is a universal adaptor pro-
tein through which most Toll-like
receptors and receptors for IL-1 and
IL-18 activate signaling pathways such
as NF-kB during normal immune innate
response (Kawai and Akira, 2010).
MYD88 coordinates the assembly of
a multi-subunit signaling complex
including the IRAK1 and IRAK4 kinase.
In ABC DLBCL cell lines, the MYD88
Table 1. MYD88 status in primary cutaneous diffuse large B-cell
lymphoma, leg type
Case no. Gender/age Site Final status (months) MYD88 (tumor) MYD88 (blood)
1 M/59 Leg DD (13) L265P NA
2 M/72 Arm DD (26) L265P No mutation
3 F/88 Arm DD (5) L265P NA
4 F/88 Leg AD (41) L265P NA
5 F/83 Trunk CR (13) L265P No mutation
6 M/62 Leg CR (31) No mutation ND
7 M/75 Arm DD (18) No mutation ND
8 F/83 Leg DA (41) No mutation ND
9 F/83 Leg DD (11) No mutation ND
10 F/88 Leg DD (39) L265P NA
11 F/81 Leg AD (17) L265P No mutation
12 F/63 Leg CR (12) L265P No mutation
13 F/75 Leg DD (66) L265P No mutation
14 F/73 Leg NA L265P NA
15 M/78 Leg DD (3) L265P No mutation
16 M/90 Leg NA No mutation ND
Abbreviations: AD, alive with disease; CR, complete remission; DA, dead of another cause; DD, dead
of disease; NA, not available; ND, not done.
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Figure 1. Clinical, histological, phenotypical features, and MYD88 analysis of case 4 (primary
cutaneous diffuse large B-cell lymphoma). (a) Violaceous and erythematous leg skin tumor.
(b) Hematoxylin, eosin, and safran (HES)–stained skin tumor section. Bar¼20 mm.
(c) Positivity of BCL2 immunostaining. Bar¼20 mm. (d) Partial sequence (sense strand) of
MYD88 exon 5 from a normal constitutional DNA, centered on codon 265, encoding a leucine (L):
the presence of a T nucleotide base at position 794 (c.794T) of the complementary DNA (cDNA)
coding sequence. (e) Partial sequence (sense strand) of MYD88 exon 5 from matching tumoral
DNA (skin biopsy), centered on codon 265: the presence of both T and C nucleotide bases
(Y¼T or C) at position 794 of the cDNA coding sequence, indicating the presence of a heterozygous
c.794 T4C nucleotide transition leading to a p.L256P—leucine to proline—mutation at amino-acid
position 265.
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L265P protein was shown to form a
stable complex containing phosphory-
lated IRAK1 and to promote NF-kB
and JAK-STAT3 signaling, conferring a
selective advantage in cell survival
(Ngo et al., 2011).
Inhibitors of IRAK4 kinase of the
MYD88 signaling complex were shown
to inhibit cell survival in nodal ABC
cell lines with MYD88 L265P mutation
(Ngo et al., 2011). The non-receptor
tyrosine kinase BTK could also repre-
sent a good target for small molecules
(Hendriks, 2011). The original high
recurrence of MYD88 L265P mutation
in PCDLBCL-LT (69%) may lead to
evaluate the potential use of such
targeted therapies.
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